Objective
This study aimed to describe the resistance pattern of both the protease (PR) and integrase (IN) coding regions in HIV-1 CRF01-AE infected patients failing LPV-based 2 nd line regimen in Cambodia.
Methods
Analysis of the Protease and Integrase drug resistance genotyping of 95 HIV-1 strains infected patients presenting detectable viral load on LPV/r-based 2 nd line regimen in Cambodia.
Results
Lack of amplification in PR gene was observed for 18/95 presenting low viral load (median VL: 2.9Log 10 copies/ ml [IQR: 2.8-3.4]). The 77 other CRF01_AE strains, harbored polymorphism mutation in position M36, H69 and L89 conferring possibly resistance to TPV/r. Fortynine (median VL: 5Log 10 copies/ml [IQR: 4 -5.5]) did not present any other PI associated resistance mutation. In contrast, 28 patients showed multiple resistances to PI. The median duration on LPV/r regimen was 34.5 months [IQR: 23.5 -53.3] and the median VL was 5Log 10 copies/ml [IQR: 4.3-5.6]. Twenty-five patients were resistant to LPV/r (7 possibly resistant). Twentyseven were resistant to IDV, 21 and 19 to ATV/r and FPV/r, respectively. Twenty-five were resistant to NFV (10 possibly), 22 resistant to SQV/r (9 possibly). Seven showed resistance to DRV/r (5 possibly). Finally, excluding possible resistance, 21/28 (75%) was resistant for at least 3 PIs. Clinical investigation revealed that most of these 28 patients starting several RTIs and PIs early around 2000. All of them were sensitive to raltegravir, elvitegravir (integrase inhibitors), and etravirine (NonNucleoside reverse transcriptase inhibitorse).
Conclusion
This study indicates that 28/95 (29.5%) of Cambodian patients presenting detectable viral load on LPV/r-based 2 nd line regimen developed resistance mutation for a large number of PIs. Most of them were not naïve for PI before LPV/r initiation. These results highlight an urgent need to evaluate the efficacy of LPV/r-based 2 nd line regimen at the national levels, allowing to design of a next 3 rd line ARV regiment in low and middle income countries. 
